NEJM Journal Watch Oncology and Hematology Top Stories of 2014

A perspective on the most important research from the past year

This year, our list of NEJM Journal Watch Oncology and Hematology top stories covers a broad range of topics and comprises summaries of studies on malignant and benign hematology as well as breast, lung, prostate, cervical, and neuroendocrine cancers. These summaries underscore our goal of identifying the most clinically relevant studies and highlighting their key points, implications, and applications. We look forward to continuing to bring you concise summaries of the most important research in oncology and hematology during the coming year.

Our Oncology and Hematology Top 10 Stories of 2014 are:

CAR-T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia

Which Myeloma Therapy for Transplant-Ineligible Patients?

Are New Oral Anticoagulants Safer Than Vitamin K Antagonists?

Exemestane for Premenopausal Breast Cancer

Is the Rising Use of Bilateral Mastectomy for Unilateral Breast Cancer Advantageous?

Crizotinib for ROS1-Mutated Non–Small-Cell Lung Cancer

Ceritinib for ALK-Rearranged Non–Small-Cell Lung Cancer

Enzalutamide Before Chemotherapy for Prostate Cancer

Bevacizumab for Advanced Cervical Cancer

Lanreotide Effective for Nonfunctional Neuroendocrine Cancers

Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)